Schonfeld Strategic Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.3M | Buy |
42,071
+1,047
| +3% | +$202K | 0.06% | 345 |
|
|
2025
Q4 | $7.54M | Sell |
41,024
-393,300
| -91% | -$69M | 0.03% | 429 |
|
|
2025
Q3 | $66.6M | Buy |
434,324
+160,534
| +59% | +$24.3M | 0.38% | 31 |
|
|
2025
Q2 | $38.3M | Buy |
273,790
+262,110
| +2,244% | +$36.7M | 0.26% | 70 |
|
|
2025
Q1 | $1.72M | Sell |
11,680
-6,470
| -36% | -$936K | 0.01% | 1024 |
|
|
2024
Q4 | $2.38M | Buy |
18,150
+7,749
| +75% | +$1.08M | 0.01% | 765 |
|
|
2024
Q3 | $1.62M | Sell |
10,401
-8,149
| -44% | -$1.32M | 0.01% | 974 |
|
|
2024
Q2 | $2.89M | Sell |
18,550
-203,425
| -92% | -$30.6M | 0.02% | 746 |
|
|
2024
Q1 | $30.1M | Buy |
221,975
+201,308
| +974% | +$26.7M | 0.2% | 94 |
|
|
2023
Q4 | $2.78M | Buy |
20,667
+4,817
| +30% | +$626K | 0.02% | 696 |
|
|
2023
Q3 | $2.15M | Sell |
15,850
-32,800
| -67% | -$4.48M | 0.02% | 810 |
|
|
2023
Q2 | $6.96M | Buy |
48,650
+44,258
| +1,008% | +$6.51M | 0.06% | 424 |
|
|
2023
Q1 | $610K | Buy |
+4,392
| New | +$591K | 0.01% | 1116 |
|
|
2022
Q3 | – | Sell |
-50,242
| Closed | -$6.64M | – | 2940 |
|
|
2022
Q2 | $6.64M | Buy |
+50,242
| New | +$6.59M | 0.06% | 386 |
|
|
2022
Q1 | – | Sell |
-57,592
| Closed | -$6.71M | – | 2584 |
|
|
2021
Q4 | $6.71M | Sell |
57,592
-19,145
| -25% | -$2.25M | 0.06% | 386 |
|
|
2021
Q3 | $9.22M | Buy |
+76,737
| New | +$8.93M | 0.1% | 279 |
|
|
2021
Q2 | – | Sell |
-51,878
| Closed | -$5.16M | – | 1935 |
|
|
2021
Q1 | $5.16M | Buy |
+51,878
| New | +$5.22M | 0.06% | 412 |
|
|
2020
Q4 | – | Sell |
-11,137
| Closed | -$1.22M | – | 1571 |
|
|
2020
Q3 | $1.22M | Buy |
+11,137
| New | +$1.24M | 0.02% | 652 |
|
|
2020
Q1 | – | Sell |
-78,677
| Closed | -$7.84M | – | 1145 |
|
|
2019
Q4 | $7.84M | Buy |
78,677
+12,176
| +18% | +$1.15M | 0.19% | 136 |
|
|
2019
Q3 | $5.93M | Buy |
66,501
+53,451
| +410% | +$4.63M | 0.17% | 152 |
|
|
2019
Q2 | $1.08M | Sell |
13,050
-6,450
| -33% | -$506K | 0.04% | 427 |
|
|
2019
Q1 | $1.58M | Buy |
+19,500
| New | +$1.54M | 0.05% | 397 |
|
|
2018
Q3 | – | Sell |
-34,450
| Closed | -$2.42M | – | 801 |
|
|
2018
Q2 | $2.42M | Buy |
+34,450
| New | +$2.48M | 0.13% | 239 |
|
|
2017
Q2 | – | Sell |
-5,000
| Closed | -$311K | – | 608 |
|
|
2017
Q1 | $311K | Hold |
5,000
| – | – | 0.03% | 463 |
|
|
2016
Q4 | $273K | Buy |
+5,000
| New | +$284K | 0.04% | 440 |
|
|
2016
Q2 | – | Sell |
-12,422
| Closed | -$699K | – | 432 |
|
|
2016
Q1 | $699K | Buy |
+12,422
| New | +$746K | 0.29% | 97 |
|
Other funds holding AZN
IA
VCM
VAM
Schonfeld Strategic Advisors's AZN Position: Q1 2026 in Review
Schonfeld Strategic Advisors increased its AstraZeneca (AZN) stake by 2.6% in Q1 2026, buying an estimated $202K and bringing the position to 42,071 shares worth $8.3M. The position accounts for 0.06% of the portfolio, ranked #345.
Schonfeld Strategic Advisors first reported a position in AZN in Q1 2016 and has held it in 26 quarters since. The position peaked at $66.6M in Q3 2025. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Schonfeld Strategic Advisors held 42,071 shares of AstraZeneca worth $8.3M as of Q1 2026.
- Schonfeld Strategic Advisors bought 1,047 AstraZeneca shares in Q1 2026, an estimated $202K.
- AstraZeneca made up 0.06% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #345 holding.
- Schonfeld Strategic Advisors first reported a position in AstraZeneca in Q1 2016 and has held it in 26 quarters since.
- Schonfeld Strategic Advisors's AstraZeneca position peaked at $66.6M in Q3 2025.
- 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.